Status:
UNKNOWN
The Efficacy of SGLT-2 Inhibitor in Patients With CAD and DM Undergoing PCI.
Lead Sponsor:
Beijing Anzhen Hospital
Conditions:
Coronary Artery Disease
Diabete Mellitus
Eligibility:
All Genders
18+ years
Brief Summary
The study is to compare the effects of SGLT-2 inhibitors and other oral hypoglycemic agents in patients with coronary heart disease and diabetes mellitus undergoing percutaneous coronary intervention.
Detailed Description
This is a single center, observational study designed to evaluate the efficacy of SGLT-2 inhibitors and other oral hypoglycemic agents in patients with coronary heart disease and diabetes mellitus who...
Eligibility Criteria
Inclusion
- Age ≥18 years
- Patients with coronary heart disease and diabetes mellitus who underwent percutaneous coronary intervention.
- Patients were provided informed consent before the procedure.
Exclusion
- History of diabetic ketoacidosis, type 1 diabetes, pancreas or beta-cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy.
- History of one or more severe hypoglycemic episode within 6 months before screening
- Ongoing, inadequately controlled thyroid disorder.
- History of hepatitis B surface antigen or hepatitis C antibody positive
- Any history of or planned bariatric surgery.
- Current use of a corticosteroid medication or immunosuppressive agent, or likely to require treatment with a corticosteroid medication.
Key Trial Info
Start Date :
September 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2024
Estimated Enrollment :
1424 Patients enrolled
Trial Details
Trial ID
NCT05333159
Start Date
September 1 2021
End Date
December 30 2024
Last Update
April 18 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Anzhen Hospital
Beijing, Beijing Municipality, China